Retatrutide

Product Information

Retatrutide is a groundbreaking triple-action peptide (C221H342N46O68, 4191.7 g/mol) that simultaneously activates GLP-1, GIP, and glucagon receptors, representing the cutting edge of metabolic research compounds. This innovative design triggers insulin release and appetite reduction through GLP-1 receptors, enhances insulin response and fat metabolism via GIP receptors, and promotes fat oxidation while maintaining glucose levels through glucagon receptor activation. Preclinical studies demonstrate significant weight reduction in laboratory models with improved metabolic markers, showing superior performance to single or dual-receptor compounds. Research applications encompass weight management mechanisms, glucose metabolism pathways, energy balance regulation, obesity research, and metabolic disease investigations. The synergistic triple-receptor approach provides unprecedented insights into integrated metabolic control. Retatrutide represents a paradigm shift in metabolic research capabilities. For laboratory research purposes only.